2021-07-29
29 July 2021Big PharmaAlex Baldwin

Is big pharma’s antidote to the COVID-19 waiver a viable alternative?

In May, a consortium of pharmaceutical companies came together to pitch a  new plan to help provide more equitable access to COVID-19 vaccines.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Big Pharma
17 May 2021   The International Association for the Protection of Intellectual Property has released a position paper on the proposed COVID-19 IP waiver, claiming that it will have a negative impact on the existing frameworks for promoting international cooperation and access to vaccines.
Big Pharma
25 May 2021   Several pharmaceutical organisations have joint-published a five-step plan to help provide more equitable access to COVID-19 vaccines that would avoid waiving IP rights.
Big Pharma
28 October 2021   UN-backed public health organisation The Medicine Patent Pool (MPP) has entered into a licence agreement with Merck Sharp & Dohme (MSD) and others to increase access to molnupiravir (MK-4482, EIDD-2801)—an investigational oral COVID-19 medicine—for low-and-middle-income countries (LMIC).

More on this story

Big Pharma
17 May 2021   The International Association for the Protection of Intellectual Property has released a position paper on the proposed COVID-19 IP waiver, claiming that it will have a negative impact on the existing frameworks for promoting international cooperation and access to vaccines.
Big Pharma
25 May 2021   Several pharmaceutical organisations have joint-published a five-step plan to help provide more equitable access to COVID-19 vaccines that would avoid waiving IP rights.
Big Pharma
28 October 2021   UN-backed public health organisation The Medicine Patent Pool (MPP) has entered into a licence agreement with Merck Sharp & Dohme (MSD) and others to increase access to molnupiravir (MK-4482, EIDD-2801)—an investigational oral COVID-19 medicine—for low-and-middle-income countries (LMIC).

More on this story

Big Pharma
17 May 2021   The International Association for the Protection of Intellectual Property has released a position paper on the proposed COVID-19 IP waiver, claiming that it will have a negative impact on the existing frameworks for promoting international cooperation and access to vaccines.
Big Pharma
25 May 2021   Several pharmaceutical organisations have joint-published a five-step plan to help provide more equitable access to COVID-19 vaccines that would avoid waiving IP rights.
Big Pharma
28 October 2021   UN-backed public health organisation The Medicine Patent Pool (MPP) has entered into a licence agreement with Merck Sharp & Dohme (MSD) and others to increase access to molnupiravir (MK-4482, EIDD-2801)—an investigational oral COVID-19 medicine—for low-and-middle-income countries (LMIC).